Influence of Adrenal Incidentalomas on Occurrence and Progression in Stroke Patients

What this Trial Is About

Researchers are investigating the link between adrenal incidentalomas (AIs), which are unexpected adrenal gland growths found during imaging done for reasons other than adrenal disease, and stroke. Stroke is a serious condition that can cause disability and death worldwide. This study aims to understand the risk of disability and death in stroke patients who also have AIs, focusing on how stroke and levels of autonomous cortisol secretion relate in these patients. The study has two parts: a retrospective cohort study conducted from April to September 2021, and a prospective cohort study planned from March 2022 to February 2024. Patients with different types of stroke—cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage—are enrolled from emergency or clinical departments. In the prospective part, patients will have their plasma cortisol levels measured after a 1-mg dexamethasone suppression test. Researchers will record detailed information about the stroke, patient characteristics, and AIs in both study parts. Participants will be monitored for up to five years to assess the incidence rate of adrenal incidentalomas and plasma cortisol levels as primary outcomes. Secondary outcomes include measuring the size of adrenal incidentalomas. Data collection includes detailed patient and disease characteristics, and assessments are performed to understand the progression and impact of AIs in stroke patients. This study does not involve interventions but observes the natural course and associations over time.

Association Between Stroke and Adrenal Incidentalomas